Benazepryl, lek dla pacjentów z przewlekłą chorobą nerek Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
kwi 13, 2010
Słowa kluczowe:
benazepryl, przewlekła choroba nerek, białkomocz, hiperpotasemia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Agresywne leczenie nadciśnienia tętniczego wywiera spowalniający wpływ na postęp przewlekłej choroby nerek (PChN). W leczeniu zarówno nadciśnienia tętniczego, jak i chorób serca i nerek zasadnicze znaczenie ma hamowanie układu renina-angiotensyna-aldosteron (RAAS). Inhibitory enzymu konwertującego (ACEi) są szczególnie korzystne u pacjentów z PChN i białkomoczem przekraczającym 1,0 g/dobę. Jednak z powodu obawy o pogorszenie wydalniczej funkcji nerek oraz o możliwość wywołania hiperpotasemii ich stosowanie jest często ograniczane. Podwyższenie stężenia kreatyniny do 30% wartości wyjściowych nie powinno stanowić powodu do przerywania leczenia ACEi. Dobór właściwego preparatu oraz jego dawkowanie odpowiednie do funkcji nerek stanowi podstawę bezpiecznego stosowania ACEi. Dieta ubogopotasowa i leki moczopędne powinny być stosowane dla uniknięcia możliwości hiperpotasemii.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Małecki , R. (2010). Benazepryl, lek dla pacjentów z przewlekłą chorobą nerek . Medycyna Faktów , 3(1(6), 61-67. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2616
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Cockcroft D.W., Gault M.H.: Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1): 31-41.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis. 2002; 39 (2 Suppl. 1): S1-S266.
3. Jungers P., Massy Z.A., Khoa T.N.: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients. A prospective study. Nephrol. Dial. Transplant. 1997; 12: 2597-2602.
4. Foley R.N., Parfrey P.S., Sarnak M.J.: Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 1998; 9: S16-S23.
5. Kirby T.: Screening for chronic kidney disease shows promise. Lancet 2010; 375: 1240-1241.
6. James M.T., Hemmelgarn B.R., Tonelli M.: Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-1309.
7. Wolf G., Butzmann U., Wenzel U.O.: The renin-angiotensin system and progresion of renal disease: from hemodynamics to cell biology. Nephron. Physiol. 2003; 93: 3-13.
8. De Cesaris R., Ranieri G., Andriani A., Lamontanara G.: Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with Diabetes. Clin. Pharm. Therap. 1996; 60: 472-478.
9. Campbell R.C., Ruggenenti P., Remuzzi G.: Halting the progression of chronic nephropathy. J. Am. Soc. Nephrol. 2002; 13: 190-5.
10. Shlipak M.G.: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Intern. Med. 2003; 138: 917.
11. Bakris G.L., Weir M.R.: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch. Intern. Med. 2000; 160(5): 685-693.
12. Pitt B., Bakris G., Ruilope L.M. et al.: Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118(16): 1643-1650.
13. Massie B.M., Armstrong P.W., Cleland J.G., Horowitz J.D., Packer M., Poole-Wilson P.A. et al.: Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch. Intern. Med. 2001; 161(2): 165-71.
14. de Zeeuw D., Lambers-Heerspink H.: Drug Dosing for Renoprotection: Maybe It’s Time for a Drug Efficacy-Safety Score? J. Am. Soc. Nephrol. 2009; 20: 688-689.
15. Shlipak M.G.: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Intern. Med. 2003; 138: 917.
16. Pelliccia F.: ACE-inhibitor of proven efficacy. MEDICI OGGI – EXTRACTS 2007; XI: 4.
17. Farmakologia inhibitorów konwertazy angiotensyny. W: Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Januszewicz A., Januszewicz W., Rużyłło W. (red.). Medycyna Praktyczna, Kraków 2005: 89-106.
18. Smith W.M., Gomez H.J.: The use of benazepril in hypertensive patients age 55 and over. Clin. Cardiol. 1991; 14 (supl. 4): IV79-IV82.
19. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334(15): 939-945.
20. Locatelli F., Del Vecchio L.: How long can dialysis be postponed by low protein diet and ACE inhibitors? Nephrol. Dial. Transplant. 1999; 14: 1360-1364.
21. Hou F.F., Zhang X., Zhang G.H. et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 2006; 354: 131-140.
22. Hou F.F., Xie D., Zhang X. et al.: L Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 2007; 18(6): 1889-98.
23. Jamerson K., Weber M.A., Bakris G.L., for the ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
24. Bakris G.L., Sarafidis P.A., Weir M.R. et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375(9721): 1173-81.
25. Bakris G.L., Toto R.D., McCullough P.A. et al.: On behalf of the GUARD Study Investigators: Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73: 1303-1309.
26. Rutkowski P., Tylicki L., Renke M. et al.: Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 2004; 43: 260.
27. Ruggenenti P., Remuzzi G.: Proteinuria: Is the ONTARGET renal substudy actually off-target? Nat. Rev. Nephrol. 2009; 5: 436-437.
28. Hebert L.A.: Optimizing ACE-inhibitor therapy for chronic kidney disease. N. Engl. J. Med. 2006; 354: 189-191.
29. Wolf G., Ritz E.: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005; 67: 798-812.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis. 2002; 39 (2 Suppl. 1): S1-S266.
3. Jungers P., Massy Z.A., Khoa T.N.: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients. A prospective study. Nephrol. Dial. Transplant. 1997; 12: 2597-2602.
4. Foley R.N., Parfrey P.S., Sarnak M.J.: Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 1998; 9: S16-S23.
5. Kirby T.: Screening for chronic kidney disease shows promise. Lancet 2010; 375: 1240-1241.
6. James M.T., Hemmelgarn B.R., Tonelli M.: Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-1309.
7. Wolf G., Butzmann U., Wenzel U.O.: The renin-angiotensin system and progresion of renal disease: from hemodynamics to cell biology. Nephron. Physiol. 2003; 93: 3-13.
8. De Cesaris R., Ranieri G., Andriani A., Lamontanara G.: Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with Diabetes. Clin. Pharm. Therap. 1996; 60: 472-478.
9. Campbell R.C., Ruggenenti P., Remuzzi G.: Halting the progression of chronic nephropathy. J. Am. Soc. Nephrol. 2002; 13: 190-5.
10. Shlipak M.G.: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Intern. Med. 2003; 138: 917.
11. Bakris G.L., Weir M.R.: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch. Intern. Med. 2000; 160(5): 685-693.
12. Pitt B., Bakris G., Ruilope L.M. et al.: Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118(16): 1643-1650.
13. Massie B.M., Armstrong P.W., Cleland J.G., Horowitz J.D., Packer M., Poole-Wilson P.A. et al.: Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch. Intern. Med. 2001; 161(2): 165-71.
14. de Zeeuw D., Lambers-Heerspink H.: Drug Dosing for Renoprotection: Maybe It’s Time for a Drug Efficacy-Safety Score? J. Am. Soc. Nephrol. 2009; 20: 688-689.
15. Shlipak M.G.: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Intern. Med. 2003; 138: 917.
16. Pelliccia F.: ACE-inhibitor of proven efficacy. MEDICI OGGI – EXTRACTS 2007; XI: 4.
17. Farmakologia inhibitorów konwertazy angiotensyny. W: Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Januszewicz A., Januszewicz W., Rużyłło W. (red.). Medycyna Praktyczna, Kraków 2005: 89-106.
18. Smith W.M., Gomez H.J.: The use of benazepril in hypertensive patients age 55 and over. Clin. Cardiol. 1991; 14 (supl. 4): IV79-IV82.
19. Maschio G., Alberti D., Janin G. et al.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334(15): 939-945.
20. Locatelli F., Del Vecchio L.: How long can dialysis be postponed by low protein diet and ACE inhibitors? Nephrol. Dial. Transplant. 1999; 14: 1360-1364.
21. Hou F.F., Zhang X., Zhang G.H. et al.: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N. Engl. J. Med. 2006; 354: 131-140.
22. Hou F.F., Xie D., Zhang X. et al.: L Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 2007; 18(6): 1889-98.
23. Jamerson K., Weber M.A., Bakris G.L., for the ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
24. Bakris G.L., Sarafidis P.A., Weir M.R. et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375(9721): 1173-81.
25. Bakris G.L., Toto R.D., McCullough P.A. et al.: On behalf of the GUARD Study Investigators: Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73: 1303-1309.
26. Rutkowski P., Tylicki L., Renke M. et al.: Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 2004; 43: 260.
27. Ruggenenti P., Remuzzi G.: Proteinuria: Is the ONTARGET renal substudy actually off-target? Nat. Rev. Nephrol. 2009; 5: 436-437.
28. Hebert L.A.: Optimizing ACE-inhibitor therapy for chronic kidney disease. N. Engl. J. Med. 2006; 354: 189-191.
29. Wolf G., Ritz E.: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005; 67: 798-812.